Progress in the diagnosis and treatment of amyloidosis;Fortschritte in der diagnostik und therapie der amyloidosen

Deutsches Arzteblatt

Volumn 103, Issue 34-35, 2006, Pages

  Schönland, Stefan O ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Amyloidosis; Cardiomyopathy; Nephrotic syndrome; Polyneuropathy; Transplantation

Indexed keywords

BORTEZOMIB; COLCHICINE; LENALIDOMIDE; MELPHALAN;

AMYLOIDOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; AUTOSOMAL DOMINANT INHERITANCE; AWARENESS; CHRONIC INFLAMMATION; CLINICAL FEATURE; CLINICAL TRIAL; DOSE RESPONSE; HUMAN; MONOCLONAL IMMUNOGLOBULINEMIA; PROGNOSIS;

EID: 33750084206     PISSN: 00121207     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Linke RP, Altland K, Ernst J et al.: Praktische Hinweise zur Diagnose und Therapie generalisierter Amyloidosen. Dtsch Arztebl 1998; 95 (42): A2626-36.
2. Kyle RA, Therneau TM, Rajkumar SV et al.: A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002; 346: 564-69.
3. Falk RH, Comenzo RL, Skinner M: The systemic amyloidoses: N Engl J Med 1997; 337: 898-909.
4. Katzmann JA, Abraham RS, Dispenzieri A, Lust JA, KyIe RA: Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem 2005; 51: 878-81.
5. Skinner M, Sanchorawala V, Seldin DC et al.: High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004; 140: 85-93.
6. Dispenzieri A, Kyle RA, Lacy MQ et al.: Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplant: A case control study. Blood 2004; 103: 3960-63.
7. Gertz MA, Merlini G, Treon SP: Amyloidosis and Waldenstrom's macroglobulinemia: Hematology. Am Soc Hematol Educ Program 2004; 257-82.
8. Perz J, Schonland SO, Hundemer M et al.: High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of AL amyloidosis: a single centre prospective phase II study. Br J Haematol 2004; 127: 543-51.
9. Schonland SO, Perz JB, Hundemer M et al.: Indications for high-dose chemotherapy with autologous stem cell support in patients with systemic amyloid light chain amyloidosis. Transplantation 2005; 80(1 Suppl.): S160-3.
10. Schonland SO, Lokhorst H, Buzyn A et al.: Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light chain amyloidosis: a report from the European Group for Blood and Marrow Transplantation. Blood 2006; 107: 2578-84.
11. Livneh A, Langevitz P, Zemer D et al.: Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 1997; 40: 1879-85.
12. Drenth JP, van der Meer JW: Hereditary periodic fever. N Engl J Med 2001; 345: 1748-57.
13. Merlini G, Bellotti V: Molecular mechanisms of amyloidosis. N Engl J Med 2003; 349: 583-96.
14. Sipe JD, Seldin DC: Xth International Symposium on Amyloid and Amyloidosis April 18-22 2004; Tours, Loire Valley, France; Amyloid 2004; 11: 268-72.
15. Hund E, Singer R, Linke RP, Willig F Grau A: Transthyretin-assoziierte hereditäre Amyloidosen. Nervenarzt 2002; 73: 930-6.
16. Lobato L, Beirao I, Silva M et al.: End-stage renal disease and dialysis in hereditary amyloidosis TTR V30M: presentation, survival and prognostic factors. Amyloid 2004; 11: 27-37.
17. Jacobson DR, Pastore RD, Yaghoubian R et al.: Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med 1997; 336: 466-73.
18. Herlenius G, Wilczek HE, Larsson M Ericzon BG: Ten ears of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry. Transplantation 2004; 77: 64-71.
19. Suhr OB, Svendsen IH, Andersson R, Danielsson A, Holmgren G, Ranlov PJ: Hereditary transthyretin amyloidosis from a Scandinavian perspective. J Intern Med 2003; 254: 225-35.
20. Palladini G, Campana C, Klersy C et al.: Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003; 107: 2440-45.
21. Dispenzieri A, Kyle RA, Gertz MA et al.: Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 2003; 361: 1787-89.
22. Gertz MA, Comenzo R, Falk RH et al.: Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10(th) International Symposium on Amyloid and Amyloidosis. Am J Hematol 2005; 79: 319-28.
23. Gillmore JD, Goodman HJ, Lachmann HJ et al.: Sequential cardiac and autologous stem cell transplantation for systemic AL amyloidosis. Blood 2006; 107: 1227-29.
24. Casserly LF, Fadia A, Sanchorawala V et al.: High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease. Kidney Int 2003; 63: 1051-57.
25. Leung N, Griffin MD, Dispenzieri A et al.: Living donor kidney and autologous stem cell transplantation for primary systemic amyloidosis (AL) with predominant renal involvement. Am J Transplant 2005; 5: 1660-70.